Evaluation of a 15‐weekCHOPprotocol for the treatment of canine multicentric lymphoma
- 2 May 2012
- journal article
- research article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 11 (4) , 306-315
Abstract
Dose intenseCHOPprotocols have been shown to improve outcome for people with non‐Hodgkin's lymphoma, but evaluation of dose intenseCHOPprotocols for canine lymphoma is currently limited. The hypothesis of this retrospective study was that a 15‐week dose intenseCHOPprotocol would have shorter treatment duration with similar efficacy to other doxorubicin‐based multidrug protocols. Thirty‐one client owned dogs with multicentric lymphoma were treated with a 15‐weekCHOPchemotherapy protocol with an overall response rate of 100% and a median progression‐free interval (PFI) of 140 days [95% confidence interval (CI) 91–335 days]. Dogs that had two or more treatment delays had significantly prolongedPFIand overall survival in multivariate analysis. Dose intensity did not correlate with patient outcome. Dogs experiencing multiple treatment delays secondary to adverse events may receive their individual maximally tolerated dose while dogs with no adverse events may be underdosed. Future studies should focus on individual patient dose optimization.Keywords
This publication has 19 references indexed in Scilit:
- Predictors of long-term survival in dogs with high-grade multicentric lymphomaJournal of the American Veterinary Medical Association, 2011
- CHOP chemotherapy for the treatment of canine multicentric T‐cell lymphomaVeterinary and Comparative Oncology, 2011
- Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 casesVeterinary and Comparative Oncology, 2010
- High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysisAnnals of Oncology, 2009
- Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancerLung Cancer, 2009
- Human granulocyte–macrophage colony‐stimulating factor DNA cationic‐lipid complexed autologous tumour cell vaccination in the treatment of canine B‐cell multicentric lymphomaVeterinary and Comparative Oncology, 2007
- Evaluation of a 6-Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with LymphomaJournal of Veterinary Internal Medicine, 2002
- Evaluation of a Discontinuous Treatment Protocol (VELCAP-S) for Canine LymphomaJournal of Veterinary Internal Medicine, 2001
- Evaluation of a High-Dose Chemotherapy Protocol with No Maintenance Therapy for Dogs with LymphomaJournal of Veterinary Internal Medicine, 2000
- Evaluation of Prognostic Factors and Sequential Combination Chemotherapy With Doxorubicin for Canine LymphomaJournal of Veterinary Internal Medicine, 1993